- Home
- SILC vs CRVO Comparison
SILC vs CRVO Comparison
Compare SILC & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | CRVO |
|---|---|---|
| Founded | 1987 | 2001 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.7M | 47.7M |
| IPO Year | 2002 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SILC | CRVO |
|---|---|---|
| Price | $19.31 | $4.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | 35.1K | ★ 97.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,737,974.00 |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.29 |
| 52 Week Low | $12.44 | $3.58 |
| 52 Week High | $23.00 | $16.50 |
Technical Indicators
Market Signals| Indicator | SILC | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.30 | 48.43 |
| Support Level | $14.45 | $4.45 |
| Resistance Level | $21.12 | $5.44 |
| Average True Range (ATR) | 1.19 | 0.48 |
| MACD | -0.23 | 0.14 |
| Stochastic Oscillator | 36.21 | 70.05 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.